Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting.

• 2024

  Sign in to bookmark this resource.

  Sign in
• Mónica López-Lacort; Cintia Muñoz-Quiles; Ainara Mira-Iglesias; F Xavier López-Labrador; María Garcés-Sánchez; Begoña Escribano-López
PMID: 39363387DOI: https://dx.doi.org/10.1542/peds.2024-066393#

---

Access Resources

• Journal ArticleEN

About

This study in Spain evaluated nirsevimab's efficacy in preventing respiratory syncytial virus infections in infants under ten months. The immunization campaign targeted all infants born after April 1st, 2023. Results showed a 75.8% effectiveness overall and 80.2% in the catch-up group. The study highlights nirsevimab's effectiveness in reducing respiratory infections and the value of catch-up immunization programs in primary care.

---

Tags

Hazard: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stages: Response; Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Immunization; Infant; Outpatients; Primary Health Care; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Spain; Immunization Programs; Antibodies, Monoclonal, Humanized

Institutions: Fisabio-Public Health; Instituto de Salud Carlos III; University of Valencia

---

More like this

Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol 2024 · Instituto de Investigación Sanitaria, World Health Organization (WHO), University of Santiago de Compostela, Instituto de Salud Carlos III Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions 2024 · University Medical Center Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---